Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markolf Hanefeld

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
Diabetes & Vascular Disease Research|January 22, 2009
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trialMarkolf Hanefeld, Avraham Karasik, Carsta Koehler, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 1, 2009
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative studyJean-Claude Ansquer, Ivan Bekaert, Martine Guy, et al.
Journal of Diabetes and Its Complications|April 25, 2006
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapyChristof Kazda, Hiltrud Hülstrunk, Karin Helsberg, et al.
Diabetes & Vascular Disease Research|November 25, 2005
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickeningKatharina Karrei, Carsta Koehler, Markolf Hanefeld, et al.
Diabetes Care|January 30, 2004
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose controlFrank Pistrosch, Jens Passauer, Sabine Fischer, et al.
Diabetes Care|March 1, 2003
Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes studyMarkolf Hanefeld, Carsta Koehler, Katja Fuecker, et al.
Clinical Laboratory|November 10, 2009
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat studyAndreas Pfützner, Karagiannis Efstrathios, Mirjam Löbig, et al.
Diabetes Care|November 24, 2016
Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114Jens Jordan, Ali El-Armouche, Markolf Hanefeld, et al.
Folia Medica|October 30, 2012
Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetesTsvetan Stefanov, Theodora Temelkova-Kurktschiev, Carsta Koehler, et al.
Diabetes Care|December 25, 2003
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesMarkolf Hanefeld, Paolo Brunetti, Guntram H Schernthaner, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
Diabetes & Vascular Disease Research|January 22, 2009
Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trialMarkolf Hanefeld, Avraham Karasik, Carsta Koehler, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|April 1, 2009
Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative studyJean-Claude Ansquer, Ivan Bekaert, Martine Guy, et al.
Journal of Diabetes and Its Complications|April 25, 2006
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapyChristof Kazda, Hiltrud Hülstrunk, Karin Helsberg, et al.
Diabetes & Vascular Disease Research|November 25, 2005
Fluctuations in glycaemia in clinical diabetes mellitus type 2 are not associated with carotid intima-media thickeningKatharina Karrei, Carsta Koehler, Markolf Hanefeld, et al.
Diabetes Care|January 30, 2004
In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose controlFrank Pistrosch, Jens Passauer, Sabine Fischer, et al.
Diabetes Care|March 1, 2003
Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes studyMarkolf Hanefeld, Carsta Koehler, Katja Fuecker, et al.
Clinical Laboratory|November 10, 2009
Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat studyAndreas Pfützner, Karagiannis Efstrathios, Mirjam Löbig, et al.
Diabetes Care|November 24, 2016
Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care 2016;39:1108-1114Jens Jordan, Ali El-Armouche, Markolf Hanefeld, et al.
Folia Medica|October 30, 2012
Association of physical activity with insulin resistance, subclinical inflammation, coagulation, and fibrinolytic biomarkers among population at high risk for type 2 diabetesTsvetan Stefanov, Theodora Temelkova-Kurktschiev, Carsta Koehler, et al.
Diabetes Care|December 25, 2003
One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesMarkolf Hanefeld, Paolo Brunetti, Guntram H Schernthaner, et al.
Pageof 13